DA
ABCL icon

Duality Advisers’s AbCellera Biologics ABCL Stock Holding History

Duality Advisers’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-68,099
Closed -$308K – 3
2024
Q1 		$308K Sell
68,099
-42,942
-39% -$219K 0.03% 515
2023
Q4 		$634K Sell
111,041
-51,159
-32% -$237K 0.07% 394
2023
Q3 		$746K Buy
162,200
+37,825
+30% +$230K 0.09% 353
2023
Q2 		$803K Sell
124,375
-2,013
-2% -$13.7K 0.1% 324
2023
Q1 		$953K Buy
+126,388
New +$1.15M 0.11% 311

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Duality Advisers's ABCL Position: Q2 2024 in Review

Duality Advisers sold out of AbCellera Biologics (ABCL) in Q2 2024, closing a stake of 68,099 shares — an estimated $308K sold.

Duality Advisers first reported a position in ABCL in Q1 2023 and held it in 5 quarters. The position peaked at $953K in Q1 2023. 146 funds tracked by Wall St. Rank hold ABCL as of Q2 2024.

  • Duality Advisers reported no remaining AbCellera Biologics position as of Q2 2024 after selling out during the quarter.
  • Duality Advisers sold 68,099 AbCellera Biologics shares in Q2 2024, an estimated $308K.
  • Duality Advisers first reported a position in AbCellera Biologics in Q1 2023 and held it in 5 quarters.
  • Duality Advisers's AbCellera Biologics position peaked at $953K in Q1 2023.
  • 146 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2024.

Based on Duality Advisers's 13F filing for Q2 2024.